2016 Endocrine Fellows Series: Pituitary Disorders

Boston, MA US

Saturday, May 14, 2016 – Saturday, May 15, 2016
Hyatt Regency Boston Hotel

The inaugural annual Endocrine Fellows Series: Pituitary Disorders is a live CME-certified conference of endocrine fellows held in Boston, Massachusetts. For details on the current and future programs, visit endocrine.org/pitfellows.

This activity is supported by educational grants from Ipsen Biopharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer, Inc.; and SANDOZ, a Novartis Company

Target Audience

This continuing medical education activity should be of substantial interest to endocrine fellows.

Learning Objectives

Upon completion of this educational activity, participants will be able to (or better able to):

  • Discuss the epidemiology of pituitary disorders to appreciate the impact on clinical practice
  • Update current knowledge of research in pituitary tumor biology and pathogenesis
  • Identify signs and symptoms of pituitary adenomas to improve early detection
  • Differentially diagnose non-functioning pituitary adenomas and select appropriate intervention
  • Formulate an individualized treatment strategy for pituitary disorders incorporating histopathological and imaging information
  • Select appropriate surgical or radiological invention to treat a pituitary adenoma and minimize long-term adverse effects
  • Discuss prevalence and endocrine consequences of TBI
  • Apply current evidence-based strategies to treat hypopituitarism in patients following TBI
  • Evaluate benefits and limitations of GH therapy in adult patients with GH deficiency
  • Recognize symptoms and potential endocrine causes of hyponatremia
  • Prepare treatment strategies to address DI and SIADH
  • Identify pituitary-associated mechanisms of hypothalamic hypogonadism
  • Select appropriate therapy to treat hypothalamic hypogonadism among current and new formulations taking patient factors into consideration
  • Select appropriate therapy to treat Cushing disease taking patient factors into consideration
  • Select appropriate treatment options for patients with acromegaly
  • Select an appropriate intervention to treat a patient with a prolactinoma taking tumor characteristics and medical response into consideration
  • Distinguish expected hormone changes from perturbations in pregnant women with pituitary disorders to assess and select treatment
  • Formulate an individualized strategy incorporating patient factors and appropriate therapeutic goals
  • Consider long-term goals when developing strategies to monitor and treat pituitary adenomas

Additional Information

Target Audience: 
Fellow
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Adrenal/HPA Axis
Quality Improvement and Healthcare Delivery
General Endocrinology
Growth Disorders
Hormones and Cancer
Neuroendocrinology and Pituitary
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 14.00 AMA PRA Category 1 Credits
  • 14.00 CME Certificate of Participation
Course opens: 
05/05/2016
Course expires: 
05/15/2017
Rating: 
5
Hyatt Regency Boston
1 Avenue de Lafayette
Boston, MA 02111
United States

Program Directors
Anne Klibanski, MD; Massachusetts General Hospital
Janet Schlechte, MD; University of Iowa Hospitals and Clinics

Presenters
Beverly MK Biller, MD; Massachusetts General Hospital/Harvard University
Michael Bliss, PhD; University of Toronto, Canada (Professor Emeritus)
Alex T Faje, MD; Massachusetts General Hospital
Ursula B Kaiser, MD; Brigham and Women’s Hospital
Anne Klibanski, MD; Massachusetts General Hospital
Karen K Miller, MD; Massachusetts General Hospital
Mark E Molitch, MD; Northwestern University Feinberg School of Medicine
Lisa B Nachtigall, MD; Massachusetts General Hospital
Janet A Schlechte, MD; University of Iowa Hospitals and Clinics
Helen A Shih, MD; Massachusetts General Hospital
Brooke Swearingen, MD; Massachusetts General Hospital
Nicholas A Tritos, MD; Massachusetts General Hospital
Joseph G Verbalis, MD; Georgetown University

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Beverly MK Biller, MD
: Consultant, Cortendo, HRA Pharma, Ipsen, Novartis; Principal Investigator, Cortendo, Novartis
Ursula Kaiser, MD: Consultant, Takeda; Scientific Advisory Board, Novo Nordisk
Mark E Molitch, MD: Consultant, Chiasma, Ipsen, Novartis, Pfizer; Primary Investigator, Chiasma, Ipsen, Novartis 
Brooke Swearingen, MD: Stockholder, Amgen, Novartis, Pfizer, Roche
Nicholas A Tritos, MD: Research Grant Support, Ipsen, Novo Nordisk, Novartis, Pfizer
Joseph G Verbalis, MD: Consultant, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Sanofi; Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi

The following faculty reported no relevant financial relationships: Michael Bliss, PhD; Alex T Faje, MD; Anne Klibanski, MD; Karen K Miller, MD; Lisa B Nachtigall, MD; Janet A Schlechte, MD; Helen A Shih, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 14.00 AMA PRA Category 1 Credits
  • 14.00 CME Certificate of Participation

Accreditation Period

Course opens: 
05/05/2016
Course expires: 
05/15/2017